LYRA

LYRA is no longer an operating biotech — it is a wind-down. In January 2026 management suspended development of LYR-210, cut 25 more staff (on top of the ~75% RIF / 87 employees after the 2024 ENLIGHTEN 1 miss), and retained the CEO and CFO merely as consultants to 'pursue strategic alternatives.' Nasdaq formally deemed the company 'a public shell' under Listing Rule 5101, issued a delisting determination, and — after LYRA withdrew its appeal — suspended trading at the open on March 17, 2026, with a Form 25 to follow. A delisted, trading-suspended shell is not a position a self-directed investor can enter or exit on an exchange; that alone makes it uninvestable.

The balance sheet confirms there is no residual equity value. Total liabilities of $46.8M exceed total assets of $36.1M, leaving stockholders' equity at -$10.7M and a liabilities/equity ratio of -4.37x. Cash of $15.9M (down 60.8% YoY) is being consumed at roughly -$28.9M of operating cash burn per year, and the accumulated deficit sits at -$434M. In any liquidation or strategic transaction, creditors stand ahead of the ~1.77M shares (already reflecting a ~97% share-count reduction, i.e. a reverse split), and common holders would most plausibly recover little to nothing.